Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001079973-25-001365 0001563786 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value 10/09/2025 false 0001843714 G26735103 Zapata Quantum, Inc. 6 Liberty Square #2488 Boston MA 02109 Constantine Christakis, Esq. 561-686-3307 Nason Yeager Gerson Harris & Fumero P.A. 3001 PGA Blvd Ste 305 Palm Beach Gardens FL 33410 0001563786 N Clark Golestani b PF N X1 36545792.00 0.00 36545792.00 0.00 36545792.00 N 22.5 IN Common Stock, $0.0001 par value Zapata Quantum, Inc. 6 Liberty Square #2488 Boston MA 02109 This amendment amends the Schedule 13D filed with the Securities and Exchange Commission on August 21, 2025. This 13D/A relates to the common stock, par value $0.0001 per share, of Zapata Quantum, Inc.,, a Delaware corporation (the "Issuer"). Clark Golestani 6 Liberty Square, #2488, Boston, MA 02109 Mr. Golestani is a director of Zapata Computing Holdings Inc During the past five years the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the past five years the Reporting Person has not been a party to a civil proceeding or a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoying future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. United States On October 9, 2025, the Reporting Person received 1,000,000 stock options, vesting in equal monthly increments over two years, with the first vesting date to occur on November 9, 2025, subject to vesting conditions. The Reporting Person is a director of the Issuer. He acquired all of his securities with the purpose of exercising control. The Reporting Person beneficially owns (i) 32,500,000 restricted shares of the Issuer's common stock, vesting in equal monthly installments over a two-year period, (ii) 151,288 additional shares of the Issuer's common stock, (iii) 34,279 shares of common stock underlying stock options exercisable until February 4, 2031, with an exercise price of $2.02 per share; (iv) 68,558 shares of common stock underlying stock options exercisable until July 31, 2033, with an exercise price of $3.80 per share; (v) 2,500,000 shares of common stock issuable upon conversion of a convertible promissory note in the principal amount of $100,000 with a conversion price of $0.04 per share, (vi) 1,250,000 shares of common stock issuable upon exercise of a five-year warrant to purchase shares of common stock with an exercise price of $0.04 per share, and (vii) 41,667 shares of common stock underlying stock options, which represent a portion of a grant of 1,000,000 stock options on October 9, 2025 with an exercise price of $0.08 per share, the remainder of which vests in equal monthly increments over two years. The above number of shares amounts to approximately 22.5% of the 158,295,506 outstanding shares of common stock as of October 14, 2025. The Reporting Person has the sole power to vote or to direct the vote, sole power to dispose or to direct the disposition of all shares beneficially owned by the Reporting Person. Except as described in this Schedule 13D under Item 3 above, the Reporting Person did not engage in any transactions in shares of the Company's common stock during the past 60 days. Not applicable. Not applicable. Not applicable. Not applicable. Clark Golestani /s/ Clark Golestani Clark Golestani, individually 10/23/2025